Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial

Hematological Oncology

Volumn 27, Issue 3, 2009, Pages 130-139

  Olioso, Paola ^a   Giancola, Raffaella ^a   Di Riti, Maria ^a   Contento, Alessandro ^a   Accorsi, Patrizia ^a   Iacone, Antonio ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Cellular therapy; CIK cells; Immunotherapy; NK T cells

Indexed keywords

ALPHA INTERFERON; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; OKT 3; PARACETAMOL; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HUMAN CELL; IMMUNOMODULATION; KIDNEY CARCINOMA; KILLER CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOMA; MALE; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BLOOD TRANSFUSION, AUTOLOGOUS; CARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LEUKOCYTE TRANSFUSION; LIVER NEOPLASMS; LYMPHOCYTES; LYMPHOMA; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 67650360317     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.886     Document Type: Article

References (29)

1. Rosenberg SA, Lotze MT, Muul LM. Observations on the systemic administration of autologous Lymphokine-activated killer cells and recombinant IL-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.
2. Rosenberg SA, Spiess PS, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocyte. Science 1986; 233: 1318-1321. (Pubitemid 16002234)
3. Schmidt-Wolf IGH, Negrin RS. Use of a SCID mouse/human lymphoma model to evaluate cytokine induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
4. Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21(13): 1673-1679. (Pubitemid 24223014)
5. Metha BA, Schmidt-Wolf IG, Weissmann IL, Negrin RS. Two pathways of exocytosis of cytoplasmatic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells. Blood 1995; 86: 3493-3499.
6. Verneris M, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic graft: purified allogeneic hematopoietic stem cells plus expanded CD8+NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001; 7: 532-542. (Pubitemid 33107563)
7. Lanier LL, Phillips JH, Hackett J, et al. Natural killer cells: definition of a cell type rather than a function. J Immunol 1986; 137: 2735. (Pubitemid 17177772)
8. Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 1995; 15(1): 33-39.
9. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92(9): 3318-3327. (Pubitemid 28492340)
10. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994; 87(3): 453-458. (Pubitemid 24230007)
11. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signalling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103: 3065-3072. (Pubitemid 38451682)
12. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in SCID mouse. J Immunol 1994; 153: 1687-1696.
13. Ma X, Chow JM, Gri G, et al. The interleukin 12p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996; 183: 147-157. (Pubitemid 26028754)
14. Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol 2001; 29: 1353-1360. (Pubitemid 34007611)
15. Edinger M, Cao Y, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence. Blood 2003; 101: 640-648. (Pubitemid 36077588)
16. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
17. Giancola R, Olioso P, Di Riti M, Capone A, Contento A, Pompetti F, Iacone A. Evaluation of an automated closed fluid management device for processing expanded cytokines induced killer cells to use in immunotherapy programs for cancer. Transfusion 2008; 48(4): 629-639.
18. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997; 74(2): 51-56.
19. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
20. Linn YC, Lau LC, Kam M, Hui. Generation of CIK cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116: 78-86.
21. Alvarnas JC, Ching Linn Y, Hope EG, Negrin RS. Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222. (Pubitemid 32433248)
22. Schmidt-Wolf IG, Finke S, Trojaneck B, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999; 81(6): 1009-1016. (Pubitemid 29516145)
23. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's Disease and non Hodgkin's Lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187. (Pubitemid 40287916)
24. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine-induced killer cells in solid and hematopoietic tumors: preliminary data [abstract]. Blood 2005; 106(Suppl 1a): 674a.
25. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis, but not signifi- cantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999; 30: 653-659. (Pubitemid 29151907)
26. Bohem U, Klamp T, Groot M, Howard JC. Cellular response to IFN-g. Annu Rev Immunol 1997; 15: 749-795.
27. Baker J, Verneris MR, Ito M, et al. Expansion of cytolytic CD8+ NK-T cells with limited capacity for Graf versus Host Disease induction due to IFN-γ. production. Blood 2001; 97: 2923-2931.
28. Takayama T, Teruaki S, Masatoshi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000; 356: 802-807. (Pubitemid 30706677)
29. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10(8): 1146-1151. (Pubitemid 38559390)